Inflammatory cytokines and cardiovascular risk

Cytokines

Volumn , Issue , 2011, Pages 235-250

  Lowe, Gordon ^a   Welsh, Paul ^a   Rumley, Ann ^a   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894439289     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Blankenberg, S. and H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, et al. 2003b. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585
2. Danesh, J. and S. Kaptoge, A.G. Mann, N. Sarwar, A. Wood, S.B. Angleman, et al. 2008. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 5: e78
3. Dixon, W.G. and K.D. Watson, M. Lunt, K.L. Hyrich, A.J. Silman, and D.P. Symmons. 2007. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56: 2905-2912
4. Emerging Risk Factors Collaboration. 2010. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132-140
5. Fibrinogen Studies Collaboration. 2005. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA 294: 1799-1809
6. Gracie, J.A. and S.E. Robertson, and I.B. McInnes. 2003. Interleukin-18. J. Leukoc. Biol. 73: 213-224
7. Grisoni, M.L. and C. Proust, M. Alanne, M. Desuremain, V. Salomaa, K. Kuulasmaa, et al. 2009. Lack of association between polymorphisms of the IL18R1 and IL18RAP genes and cardiovascular risk: the MORGAM Project. BMC Med. Genet. 10: 44
8. Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695
9. Jefferis, B.J. and P. Whincup, P. Welsh, G. Wannamethee, A. Rumley, L. Lennon, et al. 2010. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208: 557-563
10. Lakoski, S.G. and Y. Liu, K.B. Brosnihan, and D.M. Herrington. 2008. Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) study. Atherosclerosis 197: 443-447
11. Lowe, G.D. 2005. Circulating inflammatory markers and risks of cardiovascular and noncardiovascular disease. J. Thromb. Haemost. 3: 1618-1627
12. Maini, R.N. and P.C. Taylor, J. Szechinski, K. Pavelka, J. Broll, G. Balint, et al. 2006. Doubleblind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54: 2817-2829
13. Patterson, C.C. and A.E. Smith, J.W. Yarnell, A. Rumley, Y. Ben-Shlomo, and G.D. Lowe. 2010. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The Caerphilly Study. Atherosclerosis 209: 551-557
14. Pepys, M.B. and G.M. Hirschfield, G.A. Tennent, J.R. Gallimore, M.C. Kahan, V. Bellotti, et al. 2006. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221
15. Rafiq, S. and T.M. Frayling, A. Murray, A. Hurst, K. Stevens, M.N. Weedon, et al. 2007. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 8: 552-559
16. Richards, J.B. and D. Waterworth, S. O'Rahilly, M.F. Hivert, R.J. Loos, J.R. Perry, et al. 2009. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet. 5: e1000768
17. Sattar, N. and H.M. Murray, P. Welsh, G.J. Blauw, B.M. Buckley, S. Cobbe, et al. 2009a. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med. 6: e1000099
18. Sattar, N. and G. Wannamethee, N. Sarwar, J. Chernova, D.A. Lawlor, A. Kelly, et al. 2009b. Leptin and coronary heart disease: prospective study and systematic review. J. Am. Coll. Cardiol. 53: 167-175
19. Sattar, N. and G. Wannamethee, N. Sarwar, J. Tchernova, L. Cherry, A.M. Wallace, et al. 2006. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114: 623-629
20. Tzoulaki, I. and G.D. Murray, J.F. Price, F.B. Smith, A.J. Lee, A. Rumley, et al. 2006. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am. J. Epidemiol. 163: 334-341
21. Wannamethee, S.G. and G.D. Lowe, A. Rumley, L. Cherry, P.H. Whincup, and N. Sattar. 2007a. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30: 1200-1205
22. Wannamethee, S.G. and P.H. Whincup, A. Rumley, and G.D. Lowe. 2007b. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J. Thromb. Haemost. 5: 1637-1643
23. Wannamethee, S.G. and P.H. Whincup, A.G. Shaper, A. Rumley, L. Lennon, and G.D. Lowe. 2009. Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. J. Thromb. Haemost. 7: 1605-1611
24. Welsh, P. and G.D. Lowe, J. Chalmers, D.J. Campbell, A. Rumley, B.C. Neal, et al. 2008a. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39: 2226-2230
25. Welsh, P. and H.M. Murray, B.M. Buckley, A.J. de Craen, I. Ford, J.W. Jukema, et al. 2009a. Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly population. Diabetes Care 32: 308-310
26. Welsh, P. and P.H. Whincup, O. Papacosta, S.G. Wannamethee, L. Lennon, A. Thomson, et al. 2008b. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 101: 785-791
27. Welsh, P. and M. Woodward, A. Rumley, and G. Lowe. 2008c. Associations of plasma proinfl ammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br. J. Haematol. 141: 852-861
28. Welsh, P. and M. Woodward, A. Rumley, and G. Lowe. 2009b. Associations of circulating TNFalpha and IL-18 with myocardial infarction and cardiovascular risk markers: the Glasgow Myocardial Infarction Study. Cytokine 47: 143-147
29. Woodward, M. and A. Rumley, H. Tunstall-Pedoe, and G.D. Lowe. 1999. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 104: 246-257
30. Woodward, M. and P. Welsh, A. Rumley, H. Tunstall-Pedoe, and G.D. Lowe. 2009. Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10 year cohort study in Glasgow, Scotland. Eur Heart J doi: 10.1093/eurheartj/ehp115 First published online: April 10, 2009